Telemonitoring (TM) and structured telephone support (STS) have the potential to deliver specialized management to more patients with chronic heart failure (CHF), but their efficacy is still to be proven. The aim of this meta-analysis was to review randomized controlled trials (RCTs) of TM or STS for all-cause mortality and all-cause and CHF-related hospitalizations in patients with CHF, as a non-invasive remote model of a specialized disease-management intervention.
Introduction
Chronic heart failure (CHF) specialized disease management programmes improve survival and quality of life, reduce rehospitalization, and increase the implementation of evidence-based practice. 1, 2 However, most of the successful CHF disease management programmes have been built around close clinical follow-up. The need for intense face-to-face follow-up strategies limits the number of patients who can participate in these programmes.
Structured telephone support (STS) is monitoring and/or selfcare management delivered using simple telephone technology (data may have been collected and stored by a computer). Telemonitoring (TM) is digital/broadband/satellite/wireless, or blue-tooth transmission of physiological data e.g. electrocardiogram, blood pressure, weight, pulse oximetry, respiratory rate, and other data (self-care, education, lifestyle modification, and medicine administration). Both models of care have the potential to provide access to specialist care for a much larger number of patients across a much greater geography and might reduce the costs of care. These systems can assist directly in patient management, transferring the burden of care from health professionals and involve the patient in supported self-care. 3, 4 However, it is still not clear as to whether or not these interventions when delivered as the sole disease management intervention improve patient outcomes. 5, 6 This review, published in the Cochrane Database of Systematic Reviews 2010 7 updates a previously published review of remote monitoring strategies for CHF that included 10 trials of STS and five of TM. 5 Since the first review, a number of large trials have been published reporting outcomes on both STS and TM. We have focused on the same primary outcomes (all-cause mortality, CHF-related hospitalization, and all-cause hospitalization) and secondary outcomes: length of stay, health-related quality of life, healthcare costs, and acceptability of the intervention to patients with CHF. Specifically, we have examined the benefits of STS or TM on a number of important outcomes in patients with CHF when compared with standard care, where STS or TM is the primary model of specialized disease-management intervention.
Methods
As per our protocol 8 we applied the Cochrane methodology 9 for this review. 7 The specific eligibility criteria of included studies are presented in Table 1 .
Information sources and search strategies
As per the Cochrane Heart Group protocol, 9 Outcomes of STS or TM as the primary component of CHF management
Keywords included: heart failure, cardiac failure, telehealth, telephone, telemonitoring and disease-management. Language restrictions were not applied. Full details of search strategies are available. 7 
Study selection
Randomized controlled trials (RCT) of STS or TM compared with usual care were eligible to be included in the meta-analysis if they were published in full in a peer-reviewed journal. 9 Studies that were published as abstracts only were included in sensitivity meta-analyses. 9 This decision was supported by a publication, co-authored by a member of this review team, which demonstrated that substantial potential discrepancies between results presented in meeting abstracts compared with final peer-reviewed publications. 10 
Data collection process
Two expert reviewers (S.C.I. and R.A.C.) independently reviewed the results of each search according to the inclusion and exclusion criteria with a standardized data extraction tool and also applied standard scales to judge study quality and risk of bias. 9 A third reviewer (J.G.F.C.) adjudicated.
9
Data and analysis
Meta-analyses of the primary outcomes (all-cause mortality, CHF-related, and all-cause hospitalizations) were performed according to Mantel -Haenzel methods, using a fixed effects model, risk ratios (RR), intention-to-treat, and assessment of statistical heterogeneity using the I 2 statistic. 9 All analyses were performed using Review Manager (RevMan) Version 5.0 (Copenhagen: The Nordic Cochrane Centre, Cochrane Collaboration, 2008). 9 Secondary outcomes such as quality of life, cost effectiveness and adherence and acceptance were measured using multiple tools across the studies. To summarize these outcomes results have been tabulated and described. Due to variances in the way length of stay was calculated and reported in the included studies, this outcome was tabulated as opposed to pooled into a meta-analysis.
Sensitivity analysis
Data from included studies published only as abstracts were added to the meta-analyses of the primary outcomes to assess whether publication status made any difference to the result, including the level of heterogeneity. A second sensitivity analysis was performed to assess the impact of length of follow-up on the primary outcomes for full peer-reviewed publications only, excluding studies with a follow-up period of 6 months or less.
Results

Study selection
Overall, 322 publications from 7952 citations were identified as potentially relevant studies and full copies were retrieved and assessed. Exclusions are detailed in Figure 1 .
Study characteristics
Thirty RCTs of STS and TM were identified, which included 9560 participants ( Table 2) . These include 16 studies of STS 14 -18,21 -23,25 -30,32,33 (two of which were published abstracts 14, 23 ) 12 studies of TM 34 -36,38 -45,47 (three of which were published abstracts 36, 43, 47 ), and two studies with both STS and TM intervention arms compared with usual care. 11, 13 The included populations were from seven countries ( Table 2) . Twenty-five studies were published as full peer-reviewed publications (16 STS, n ¼ 5613 and 11 TM, n ¼ 2710). Two studies 11, 13 had two separate intervention arms (STS vs. TM vs. usual care) and each was considered as a separate comparison with usual care (and are included in the aforementioned counts). One study included two STS arms, one of which used standard telephone equipment and the other a videophone; for our analyses these two intervention arms were combined as STS. 33 
Risk of bias
Analysis of the distribution in the funnel plots (not shown) demonstrated a strong publication bias towards positive outcomes in the included studies. 7, 9 A summary of the risk of bias analysis is presented in Table 3 . The heterogeneity within the studies ranged from low (for all-cause mortality,
All-cause mortality 
Chronic heart failure-related hospitalization
Thirteen studies of STS 11,13,15,16,21,22,25 -30,32 and four studies of Addition of one STS study published as an abstract 23 did not alter the result of the meta-analysis other than to reduce heterogeneity (I 2 ¼ 0%). Addition of two TM studies published as abstracts 43, 47 to the meta-analysis marginally improved the effect [RR 0. 
All-cause hospitalization
Eleven studies of STS 11,13,16,21,22,25,28 -30,32,33 and eight studies of TM 11,13,34,40 -42,44,45 examined the effect of these interventions on the proportion of participants with at least one hospitalization for any cause (Figure 4 ). Outcomes of STS or TM as the primary component of CHF management
Length of stay
Only one STS study 32 reported a statistically significant reduction in the length of stay for patients in the intervention group compared with those receiving usual care. One study reported a substantial difference in the number of hospital days per patient. 43 
Health-related quality of life
Sixteen studies reported quality of life. 
Cost
Twelve studies (nine STS 15,18,20,25,27 -29,31 -33 and three TM 35, 40, 42 ) provided details on cost of the intervention or cost reductions associated with the intervention or cost effectiveness. The cost of the interventions varied according to the type of intervention, in particular the technologies used and the intensity at which it was delivered. Of the 11 studies which reported the effect of the intervention on the cost of care, 18,20,25,27 -29,32,33,35,40,42 all but three, 18, 20, 29, 35 reported reductions in cost (either cost per admission or overall reduction in healthcare costs), with those reporting per cent reductions ranging between 14% 25 and 86%. 33 
Other outcomes
Few studies reported adherence to the intervention (compliance). Among those that did, 13, 24, 38, 39, 41, 44 adherence was measured at 65.8% for STS, 24 and 75% to 98.5% for TM. 13, 38, 39, 41, 44 The adaptation to the technology was high, with two studies, reporting that 96 -97% of patients (often aged .70 years) were able to learn and use the STS or TM systems. 12, 24 Acceptance (satisfaction) of patients receiving healthcare via STS or TM was rated Figure 2 Effect of structured telephone support and telemonitoring on all-cause mortality. 7 Copyright Cochrane Collaboration, reproduced with permission.
Outcomes of STS or TM as the primary component of CHF management between 76% 24 and 100%. 12, 24, 35, 42, 45 Improvements in other outcomes from these trials included: New York Heart Association (NYHA) functional class that improved in three 14, 18, 27 studies.
Chronic heart failure knowledge and self-care improved in both studies reporting this outcome; 17,35 6 min walk test improved in one study, 27 of the two 18 that reported this outcome; improvements in evidence-based pharmacotherapy were seen in six 18, 21, 22, 25, 27, 42 of the seven studies 16 that reported this outcome and the only study to report brain natriuretic peptide, reported an improvement in this measure. 37 
Discussion
This systematic review and meta-analysis suggests that both TM and STS have a broad range of benefits for patients with heart failure: including a substantial reduction in all-cause mortality for TM, a substantial reduction in the risk of CHF hospitalization for both TM and STS and a modest reduction in the risk of all-cause hospitalization. These interventions improved quality of life, reduced costs, and were acceptable to patients. Improvements in prescribing, patient knowledge and self-care, and functional class were observed. The precise mechanisms by which these interventions produce these effects are unclear but probably reflect a combination of improved implementation of and adherence to guideline therapies, early identification of complications or disease progression, and a positive impact on patient psychology. 48 Patients in these trials reported a sense of reassurance and security, feeling that they have a lifeline to expert care. 23, 27 Two substantial studies 49, 50 have been reported since this review was completed and will be incorporated in the next revision which is currently underway. The Tele-HF study 49 which included 1653 patients, was a study of a voice interactive system (STS) applied to patients recently discharged from hospital after an episode of worsening heart failure. Adherence with the system was very poor, suggesting that patients did not engage with the service, perhaps because of the nature of the technology. No benefits were observed on death or hospitalization. This is consistent with the results of our systematic review, 7,51 at least with respect to mortality. The TIM-HF study, 50, 52, 53 including 710 patients, was a TM study of patients with exceptionally wellmanaged chronic stable heart failure monitored by a remote expert group. Trends to fewer deaths and hospitalizations with TM were not significant; suggesting that home TM might not be an effective intervention in stable patients when other systems have ensured a high quality of care. However, TM might be a more efficient and less expensive option when the quality of care is not of a similar standard to that provided in TIM-HF. Also, it is unclear as to whether home TM is most successfully deployed as an adjunct to personalized care from a local specialist clinic or as a remote a regional or national service.
We excluded from this analysis other methods of follow-up and management that have also been reported to improve outcomes, such as nurse-led or specialist heart failure clinic or home visits. 2 It is possible that intensified self-management and remote management are the key factors driving clinical benefit with these interventions. If so, the main issues revolve around an organization and cost effectiveness. The most expensive aspect of healthcare in high-income countries is staff to run services and deliver care. Delivering care by increasing direct one-to-one interactions is likely to be an expensive long-term strategy. Development of TM systems that support the patient directly in making decisions about issues such as diuretic dose, diet, and life-style and when to seek professional advice have the potential to offer expert care to most patients with CHF. Implementation of TM will require a change in the approach of healthcare systems to the delivery of care with redeployment of existing staff rather than an expansion of the healthcare work force required by other strategies. Indeed, it is quite likely that TM has not worked optimally in clinical trials since the studies were generally done in parallel to rather than integrated with existing services. Restructuring healthcare around TM could be more effective and cost efficient.
An additional and increasingly apparent dimension to TM is that it is a direct investment in the patient rather than in healthcare services. The patient is less likely to be a passive recipient of services from health professionals, and becomes more actively involved in their care. Patients provide information on symptoms and vital signs and receive feedback and education, which they can review at their leisure as often as they wish and together with their carers and family. More advanced systems will ensure that the patients know when and how medication should be adjusted and when they can do this themselves and when they need professional support. Because the patients know what care they should receive, health professionals may be more likely to deliver it or explain why the patients should deviate from the plan. Telemonitoring will create more expert patients. Undoubtedly, this will create headaches for health professionals, leading to resistance to change. Outcomes of STS or TM as the primary component of CHF management
The medical profession should offer the best service to patients even if this means moving out of their professional comfort zone.
Compared with other recent systematic reviews of remote monitoring in CHF, 54, 55 our review 7 is unique in using robust Cochrane methodology. 8, 9 We have synthesized and quantified the benefits of STS and TM, while limiting the influence of confounders such as home-visits by specialized healthcare staff or frequent visits to a specialized CHF clinic on the efficacy of these interventions in managing patients with CHF. Previous reviews on this topic have included a mixture of research methods (RCTs and cohort studies) and studies of both invasive and noninvasive remote monitoring, many of which have involved home visits. 54, 55 These findings have important clinical implications. The findings of this review are highly relevant to the future planning and implementation of CHF disease-management globally. This analysis provides strong evidence that these technologies reduce mortality and hospitalizations as well as improving measures such as quality of life. There may be benefits of using these technologies to manage patients with CHF that relate to human or financial resources, but perhaps the biggest advantage can be gained from utilizing these technologies to reach patients with CHF who are without access to home or clinic-based CHF-management programmes.
3,4 Such benefits may not be restricted to high-income countries. Indeed, China and India 56 both have programmes for delivering care remotely. The average age of patients in these included trials ranged from 45 to 78 years, with the majority of patients aged .68 years. It is clear that many older people are able to use and benefit from STS and TM. In fact TM devices are usually designed specifically with older people in mind.
Our synthesis of the evidence of STS and TM is only as good as the included studies. We were limited by the format of published results, especially for those where we were unsuccessful in obtaining further study details. In addition, the heterogeneity is large for some of the meta-analyses of the primary outcomes. This heterogeneity is not only within methodology but also the types and intensity of applied technologies.
There was evidence of publication bias. It is likely that many small studies are never published, either because the investigator does not offer their results for publication or because editors reject under-powered and negative studies. There is a dearth of evidence about how long patients should be supported by TM or STS. It is possible that the greatest benefit in terms of education and medication patterns is accrued within a few weeks and that long-term monitoring is redundant. However, the weight monitoring in heart failure trial showed that a 6-month TM intervention was associated with a reduction in mortality but that withdrawal led to rapid loss of this initial benefit, suggesting that long-term TM might be superior to short-term TM. 57 In conclusion, STS and TM improve outcomes for patients with CHF, although only TM appears to have a substantial impact on reducing mortality. This may reflect the impact of improved access to specialist care, which could be delivered by more conventional means but at additional cost. The effects appear substantial and might be an underestimate of the true impact when properly integrated into care pathways. Given the wealth of evidence and the impact on hospitalization that is likely to mitigate costs, all patients with CHF should have access to enhanced surveillance.
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